These technologies have strong potential for therapeutic gene therapy, although it must be said that their application in humans, particularly human embryos, raises considerable ethical questions. Theoretically speaking, in the case of gene duplications that lead to developmental disorders, corrective gene therapy applied at an early developmental stage might potentially prevent, to some extent, the development abnormalities caused by high levels of a protein (in this case MECP2). Also theoretically, post-natal gene editing might have positive effects in these cases, for example if the disease phenotype is being permanently reinforced after birth by the duplication.
But it's very early days for the technology and its application in humans are still only starting to be explored.
These genome editing technologies have the capacity for gene deletion, but its application in humans, particularly human embryos, raises considerable ethical questions. Because of the relatively novelty of this technology these questions are only just starting to be debated, although there are already a handful of studies of genome editing in humans reported in the literature.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used
to help us achieve the features and activities described below. To learn more about how these trackers help us
Register to Nature Portfolio Bioengineering Community
The Nature Portfolio Bioengineering Community is a community blog for readers and authors of Nature Research journals, including Nature Biomedical Engineering, Nature Biotechnology, Nature Communications, Nature Medicine, and others. Become a member, and contribute with research news and stories.